Strategic Partnerships Position Cellistic as a preferred partner for biotech firms developing iPSC-based or allogeneic cell therapies, highlighting its expertise in process development, manufacturing scaling, and access to sister company Ncardia’s knowledge transfer.

Off-the-shelf Platforms Leverage their Echo Platform and Allo Chassis offerings to pursue customers seeking ready-to-use, immune-shielded iPSC lines, emphasizing cost-effective development paths and accelerated timelines for new cell therapies.

Tremendous Target Market Focus on collaborations with early to mid-stage cell therapy developers seeking scalable iPSC-derived products, including Treg and other immune-modulatory therapies, aligned with Cardiology, Oncology, and Autoimmune indications.

Global Capabilities Highlight cross-border capabilities between Netherlands, Belgium, and allied partners to support international GMP manufacturing, regulatory readiness, and tech transfers for global programs.

Financial Growth Path Capitalize on low current revenue but high upside by targeting strategic collaborations, licensing, or contract manufacturing agreements that convert pilot programs into larger-scale production for partners with upcoming clinical trials.